|
|
|
Insider
Information: |
Powell Michael |
Relationship: |
10% Owner |
City: |
San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
21 |
|
Direct
Shares |
22,645,475 |
|
Indirect Shares
|
6,181,468 |
|
|
Direct
Value |
$15,689,187 |
|
|
Indirect Value
|
$148,316,858 |
|
|
Total
Shares |
28,826,943 |
|
|
Total
Value |
$164,006,045 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
2
|
Stock
price went up :
|
0
|
2
|
Stock
price went down : |
1
|
0
|
|
|
|
Gain/Loss Ratio : |
-1.0
|
2.0
|
Percentage
Gain/Loss : |
-63.7%
|
32.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Seagen Inc |
SGEN |
Director |
2004-12-16 |
20,001 |
2004-12-16 |
647,577 |
Premium* |
|
Molecular Templates, Inc. |
MTEM |
Director |
2005-03-08 |
3,440,201 |
2006-03-16 |
12,846 |
Premium* |
|
Anesiva Inc |
ANSVQ |
Director, 10% Owner |
2007-12-18 |
65 |
2007-12-18 |
4,906,973 |
Premium* |
|
Paratek Pharmaceuticals Inc |
PRTK |
10% Owner |
2006-05-09 |
43,213 |
|
0 |
Premium* |
|
Orexigen Therapeutics, Inc. |
OREX |
Director |
2010-12-23 |
1 |
2010-12-23 |
0 |
Premium* |
|
Trius Therapeutics Inc |
TSRX |
Director |
2010-08-06 |
0 |
2012-03-26 |
9,302 |
Premium* |
|
Humanigen Inc |
HGEN |
10% Owner |
2013-02-05 |
414,394 |
2013-02-05 |
0 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
Director |
2016-07-29 |
0 |
2016-10-31 |
14,328 |
Premium* |
|
Aravive Inc |
ARAV |
10% Owner |
2014-03-26 |
2,146,978 |
2014-03-26 |
0 |
Premium* |
|
Hyperion Therapeutics Inc |
HPTX |
10% Owner |
2015-05-07 |
0 |
2014-06-04 |
0 |
Premium* |
|
Aerie Pharmaceuticals Inc |
AERI |
10% Owner |
2014-07-10 |
0 |
2014-07-09 |
0 |
Premium* |
|
Marinus Pharmaceuticals Inc |
MRNS |
10% Owner |
2014-08-05 |
0 |
2016-10-20 |
15,470 |
Premium* |
|
Synlogic Inc |
SYBX |
Director |
2015-10-05 |
0 |
2018-01-26 |
574,972 |
Premium* |
|
Aclaris Therapeutics, Inc. |
ACRS |
10% Owner |
2015-10-13 |
2,289,480 |
2015-10-13 |
0 |
Premium* |
|
Entasis Therapeutics Holdings Inc. |
ETTX |
10% Owner |
2018-09-28 |
1,180,178 |
2018-09-28 |
0 |
Premium* |
|
Nextcure, Inc. |
NXTC |
10% Owner |
2019-11-15 |
2,671,856 |
2019-11-15 |
0 |
Premium* |
|
Iterum Therapeutics Plc |
ITRM |
10% Owner |
2020-06-02 |
1,226,514 |
2020-06-01 |
0 |
Premium* |
|
Akouos, Inc. |
AKUS |
10% Owner |
2020-06-30 |
1,515,073 |
2020-06-30 |
0 |
Premium* |
|
Inozyme Pharma, Inc. |
INZY |
10% Owner |
2020-07-28 |
2,028,308 |
2020-07-28 |
0 |
Premium* |
|
Bolt Biotherapeutics, Inc. |
BOLT |
10% Owner |
2021-02-09 |
2,754,437 |
2021-02-09 |
0 |
Premium* |
|
Vera Therapeutics, Inc. |
VERA |
10% Owner |
2021-05-18 |
2,914,776 |
2021-05-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
126 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SGEN |
Seagen Inc |
Director |
|
2004-08-19 |
4 |
S |
$6.75 |
$50,665 |
I/I |
(7,500) |
1,461,999 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-20 |
4 |
S |
$6.75 |
$121,500 |
I/I |
(18,000) |
1,444,494 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-23 |
4 |
S |
$6.75 |
$489,500 |
I/I |
(72,000) |
1,374,474 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-24 |
4 |
S |
$6.85 |
$213,270 |
I/I |
(31,000) |
1,344,326 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-25 |
4 |
S |
$6.85 |
$140,525 |
I/I |
(20,500) |
1,324,390 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-26 |
4 |
S |
$6.75 |
$60,780 |
I/I |
(9,000) |
1,315,638 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-08-27 |
4 |
S |
$6.75 |
$37,125 |
I/I |
(5,500) |
1,310,289 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-09-02 |
4 |
S |
$6.60 |
$171,975 |
I/I |
(26,000) |
1,285,004 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-09-15 |
4 |
S |
$6.70 |
$6,700 |
I/I |
(1,000) |
1,284,032 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-09-16 |
4 |
S |
$6.70 |
$154,160 |
I/I |
(23,000) |
1,261,664 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-09-17 |
4 |
S |
$6.70 |
$211,525 |
I/I |
(31,500) |
1,231,030 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-09-21 |
4 |
S |
$6.70 |
$259,005 |
I/I |
(38,500) |
1,193,589 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-09-23 |
4 |
S |
$6.75 |
$385,918 |
I/I |
(55,988) |
1,139,113 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-09-23 |
4/A |
S |
$0.00 |
$0 |
I/I |
(0) |
1,140,101 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-09-24 |
4 |
S |
$6.92 |
$69,200 |
I/I |
(10,000) |
1,129,388 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-09-29 |
4 |
S |
$6.65 |
$333,730 |
I/I |
(50,000) |
1,080,763 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-11-11 |
4 |
S |
$6.70 |
$16,750 |
I/I |
(2,500) |
1,079,320 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-11-12 |
4 |
S |
$6.70 |
$362,350 |
I/I |
(54,000) |
1,026,805 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-11-15 |
4 |
S |
$6.70 |
$609,619 |
I/I |
(89,500) |
939,766 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-11-16 |
4 |
S |
$6.90 |
$372,845 |
I/I |
(54,000) |
887,251 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-11-29 |
4 |
S |
$7.00 |
$49,160 |
I/I |
(7,000) |
880,443 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-12-01 |
4 |
S |
$6.90 |
$176,300 |
I/I |
(25,500) |
855,644 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-12-02 |
4 |
S |
$6.91 |
$414,999 |
I/I |
(59,300) |
797,975 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-12-03 |
4 |
S |
$7.00 |
$482,525 |
I/I |
(68,200) |
731,650 |
|
- |
|
SGEN |
Seagen Inc |
Director |
|
2004-12-06 |
4 |
S |
$7.25 |
$55,800 |
I/I |
(7,500) |
724,356 |
|
- |
|
126 Records found
|
|
Page 3 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|